1642-1643 / 2351
Kidney toxicity
• Grade 3 4 hypomagnesemia
-
in 2-6% treated with mab’s
• G3-4 in a controlled setting:
< 3 mo cetuximab: 0 5%
.
-
3-6 mo. cetuximab: 3-23%
> 6
t i
b 12 47%
mo. ce ux ma : -
Ti d
l
• re ness, somno ence,
seizures, cardiac arrythmias